Jennifer L DePry1, Ritva Vyas2, Hillard M Lazarus3, Paolo F Caimi3, Meg R Gerstenblith2, Jeremy S Bordeaux2. 1. Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio. 2. Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio2Case Comprehensive Cancer Center, Cleveland, Ohio. 3. Case Comprehensive Cancer Center, Cleveland, Ohio3Division of Hematology and Oncology, Department of Internal Medicine, University Hospitals Case Medical Center, Cleveland, Ohio.
Abstract
IMPORTANCE: Hematopoietic cell transplantation has increased the survival of patients with several types of malignant hematologic disease and hematologic disorders; however, these patients have an increased risk of posttransplant cutaneous malignant neoplasms. Physicians should be aware of associated risk factors to provide appropriate patient screening and long-term care. OBJECTIVE: To identify the incidence and risk factors for cutaneous malignant neoplasms following hematopoietic cell transplantation. EVIDENCE REVIEW: A systematic review was conducted using Medline and Cochrane databases from January 1995 to December 2013. Retrospective and prospective reviews containing at least 100 patients who underwent hematopoietic cell transplantation reporting skin cancer as a primary outcome were included. Information regarding the entire cohort, data for the subset who developed cutaneous malignant neoplasms, and cutaneous malignant neoplasm risk factors were extracted from included articles. The level of evidence for each study was assessed using the Strength of Recommendation Taxonomy scale. FINDINGS: Patients who underwent hematopoietic cell transplantation had an increased risk of squamous cell carcinoma, basal cell carcinoma, and melanoma. Factors such as primary disease, chronic graft-vs-host disease, prolonged immunosuppression, radiation exposure, light skin color, sex, and T-cell depletion are risk factors for cutaneous malignant neoplasms. CONCLUSIONS AND RELEVANCE: Given the increased risk of cutaneous malignant neoplasms in hematopoietic cell transplant recipients, this population should be educated on skin self-examination and pursue regular follow-up with dermatologists.
IMPORTANCE: Hematopoietic cell transplantation has increased the survival of patients with several types of malignant hematologic disease and hematologic disorders; however, these patients have an increased risk of posttransplant cutaneous malignant neoplasms. Physicians should be aware of associated risk factors to provide appropriate patient screening and long-term care. OBJECTIVE: To identify the incidence and risk factors for cutaneous malignant neoplasms following hematopoietic cell transplantation. EVIDENCE REVIEW: A systematic review was conducted using Medline and Cochrane databases from January 1995 to December 2013. Retrospective and prospective reviews containing at least 100 patients who underwent hematopoietic cell transplantation reporting skin cancer as a primary outcome were included. Information regarding the entire cohort, data for the subset who developed cutaneous malignant neoplasms, and cutaneous malignant neoplasm risk factors were extracted from included articles. The level of evidence for each study was assessed using the Strength of Recommendation Taxonomy scale. FINDINGS:Patients who underwent hematopoietic cell transplantation had an increased risk of squamous cell carcinoma, basal cell carcinoma, and melanoma. Factors such as primary disease, chronic graft-vs-host disease, prolonged immunosuppression, radiation exposure, light skin color, sex, and T-cell depletion are risk factors for cutaneous malignant neoplasms. CONCLUSIONS AND RELEVANCE: Given the increased risk of cutaneous malignant neoplasms in hematopoietic cell transplant recipients, this population should be educated on skin self-examination and pursue regular follow-up with dermatologists.
Authors: Jop C Teepen; Judith L Kok; Leontien C Kremer; Wim J E Tissing; Marry M van den Heuvel-Eibrink; Jacqueline J Loonen; Dorine Bresters; Helena J van der Pal; Birgitta Versluys; Eline van Dulmen-den Broeder; Tamar Nijsten; Michael Hauptmann; Nynke Hollema; Wil V Dolsma; Flora E van Leeuwen; Cécile M Ronckers Journal: J Natl Cancer Inst Date: 2019-08-01 Impact factor: 13.506
Authors: J S Song; W B London; E B Hawryluk; D Guo; M Sridharan; D E Fisher; L E Lehmann; C N Duncan; J T Huang Journal: Bone Marrow Transplant Date: 2017-04-03 Impact factor: 5.483
Authors: Elizabeth L Yanik; Ruth M Pfeiffer; D Michal Freedman; Martin A Weinstock; Elizabeth K Cahoon; Sarah T Arron; Matthew Chaloux; M Kari Connolly; Priyadharsini Nagarajan; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-04-04 Impact factor: 4.254
Authors: Jeffrey F Scott; Kevin R Brough; Konstantin V Grigoryan; John G Muzic; Grace Y Kim; Rosalynn R Z Conic; Sheena T Hill; Jerry D Brewer; Christian L Baum; Mark R Litzow; William J Hogan; Mrinal S Patnaik; Shahrukh K Hashmi; Hillard M Lazarus; Jeremy S Bordeaux; Cheryl L Thompson; Meg R Gerstenblith; Julia S Lehman Journal: JAMA Dermatol Date: 2020-06-01 Impact factor: 10.282
Authors: Shalaka S Hampras; Frederick L Locke; Julio C Chavez; Nishit S Patel; Anna R Giuliano; Kyle Miller; Tarik Gheit; Massimo Tommasino; Dana E Rollison Journal: Leuk Lymphoma Date: 2017-07-06